BioPharmSignal logoBioPharmSignal

Biotech News

Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

Foghorn Therapeutics (FHTX)Foghorn TherapeuticsCompany update

- Complete and durable regression and anti-tumor immune memory following treatment with FHD-909 (LY4050784) in combination with an anti-PD-1 antibody in preclinical syngeneic mouse models - Selective CBP degrader FHT-171 shows strong anti-tumor activity and favorable tolerability in preclinical

Related news

FHTXFoghorn Therapeutics2026-08-06 11:00 EST

Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update

FHTXFoghorn Therapeutics2026-06-05 11:00 EST

Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026

KYMRKymera2026-06-08 11:00 EST

Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses

KYMRKymera2026-06-12 11:00 EST

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

FATEFate Therapeutics2026-06-04 12:30 EST

Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting

CGEMCullinan Therapeutics, Inc.2026-07-28 11:00 EST

Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML

FATEFate Therapeutics2026-07-06 12:30 EST

Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting

NRIXNurix Therapeutics2026-06-11 11:00 EST

Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy

CGEMCullinan Therapeutics, Inc.2026-06-10 11:30 EST

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases

NRIXNurix Therapeutics2026-07-21 20:01 EST

Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

View all latest news

Foghorn Therapeutics

Foghorn Therapeutics is an oncology company focused on chromatin biology and gene-regulation targets. Its platform seeks to create differentiated cancer therapies through epigenetic control.

Recent company news

FHTXFoghorn Therapeutics2026-08-06 11:00 EST

Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update

FHTXFoghorn Therapeutics2026-06-05 11:00 EST

Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026

FHTXFoghorn Therapeutics2026-05-12 11:00 EST

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May

FHTXFoghorn Therapeutics2026-05-07 11:00 EST

Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update

FHTXFoghorn Therapeutics2026-04-21 20:05 EST

Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

Stock data

Close
5.57 USD
Market cap
213.13M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States